FindTrial
Sign In

AI-Driven Cross-Modal Topological Tool of the “Microbiome–Host–Immunity” Axis for Precision Therapy Initiation in Immune-Related Colitis

AI-Driven Cross-Modal Topological Tool of the “Microbiome–Host–Immunity” Axis for Precision Therapy Initiation in Immune-Related Colitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120804
Enrollment
Unknown
Registered
2026-03-19
Start date
2026-03-19
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune checkpoint inhibitor-related Colitis

Interventions

Hormone/biological agent treatment - effective/ineffective observation group:None

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18 - 75 years old; 2. Received anti-PD-1/anti-PD-L1/anti-CTLA-4 treatment and diagnosed with >=G2 grade irAE colitis

Exclusion criteria

Exclusion criteria: 1.Patients with inflammatory bowel disease; 2.Gastrointestinal infections; 3.Recent use of antibiotics or probiotics;

Design outcomes

Primary

MeasureTime frame
Clinical parameters and treatment data;—

Countries

China

Contacts

Public ContactTan Bei

Peking Union Medical College Hospital, Chinese Academy of MedicalSciences

tanbei0626@aliyun.com+86 10 6915 5017

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026